Millendo Therapeutics, Inc. (MLND) Research

Millendo Therapeutics, Inc. is an advanced biopharmaceutical firm dedicated to developing innovative therapies for rare hormonal disorders, primarily within the United States. The company's key therapeutic candidates include livoletide, an investigational drug aimed at Prader-Willi syndrome; nevanimibe, an experimental compound designed for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist intended to alleviate vasomotor symptoms (such as hot flashes) in women experiencing menopause. This enterprise maintains its primary operational base in Ann Arbor, Michigan.

Market snapshot

Symbol
MLND
Price
$1.06
Day change
-5.36%
Market cap
$11.1M
P/E ratio
-0.27x
52-week range
1.06-1.13
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Applied Molecular Transport Inc. (AMTI)
  • Cyclacel Pharmaceuticals, Inc. (CYCC)
  • Gelesis Holdings, Inc. (GLS)
  • TuHURA Biosciences, Inc. (HURA)
  • Korro Bio, Inc. (KRRO)
  • Notable Labs, Ltd. (NTBL)
  • ObsEva S.A. (OBSV)
  • Scorpius Holdings, Inc. (SCPX)

Recent insider activity

  • Nuechterlein Carole — A-Award (12000 shares) on 2020-06-22
  • HOWE JOHN P MD — A-Award (12000 shares) on 2020-06-22
  • Gallagher Carol Giltner — A-Award (12000 shares) on 2020-06-22
  • NICHOL GEOFFREY — A-Award (12000 shares) on 2020-06-22
  • Hindman James M. — A-Award (12000 shares) on 2020-06-22

Open Millendo Therapeutics, Inc. (MLND) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.